F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 1.54 EUR 2.67% Market Closed
Market Cap: 570.4m EUR
Have any thoughts about
Fluidigm Corp?
Write Note

Fluidigm Corp
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fluidigm Corp
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Net Change in Cash
$128m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
27%
Thermo Fisher Scientific Inc
NYSE:TMO
Net Change in Cash
-$1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Danaher Corp
NYSE:DHR
Net Change in Cash
-$9.7B
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Net Change in Cash
$1.9m
CAGR 3-Years
-60%
CAGR 5-Years
N/A
CAGR 10-Years
-25%
Agilent Technologies Inc
NYSE:A
Net Change in Cash
$450m
CAGR 3-Years
85%
CAGR 5-Years
N/A
CAGR 10-Years
22%
IQVIA Holdings Inc
NYSE:IQV
Net Change in Cash
$348m
CAGR 3-Years
287%
CAGR 5-Years
57%
CAGR 10-Years
26%
No Stocks Found

Fluidigm Corp
Glance View

Market Cap
569.7m EUR
Industry
Life Sciences Tools & Services

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
1.08 EUR
Overvaluation 30%
Intrinsic Value
Price
F

See Also

What is Fluidigm Corp's Net Change in Cash?
Net Change in Cash
128m USD

Based on the financial report for Jun 30, 2024, Fluidigm Corp's Net Change in Cash amounts to 128m USD.

What is Fluidigm Corp's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
27%

Over the last year, the Net Change in Cash growth was 89%.

Back to Top